• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » inVentiv Health, NeuroVive Pharmaceutical extend partnership

inVentiv Health, NeuroVive Pharmaceutical extend partnership

February 3, 2014
CenterWatch Staff

inVentiv Health, offering best-in-class clinical, commercial and consulting services, has extended its partnership with NeuroVive Pharmaceutical, a publicly-traded Swedish biotech firm specializing in drugs that treat acute cardiovascular and neurological conditions.

inVentiv Health works with pharmaceutical and biotechnology firms to help define innovative alternatives to traditional development and commercialization models. inVentiv offers mid-size pharmaceutical and biopharmaceutical companies an expansive set of services that run from early-stage clinical development to full global commercialization. The breadth of inVentiv Health's services is unique in the industry and includes comprehensive drug development, risk management, market access and reimbursement, launch, marketing communications, payer relations and patient outcomes. 

NeuroVive, with a portfolio of mitochondrial drugs in development to treat acute cardiovascular and neurological conditions, has been evaluating various collaborations with large pharmaceutical companies and CROs to reduce risk and increase cost efficiencies. It currently is in the planning stage for commercialization of its lead product, CicloMulsion, now in a phase III study to determine the drug's effectiveness in reducing cardiac damage following stenting in heart attack patients.

NeuroVive is looking for a partner with an alternative business model that can commercialize CicloMulsion and be leveraged to scale for future products. By working with inVentiv, mid-size pharmaceutical companies maintain more control and value with the ability to move faster to market.

"We're big enough to step in and provide NeuroVive with virtually any service they require to develop and commercialize their compound, and we're flexible enough to align with whatever they need to achieve their objectives," said Dan Feldman, president of inVentiv Health Europe. "Pharmaceutical companies face a far more challenging market environment than ever before. Today's market requires innovative strategic partnerships. inVentiv Health was created to provide this new model for the new marketplace."

NeuroVive already is accessing inVentiv services and recently completed a one-year regulatory consulting project with ParagonRx, inVentiv's risk mitigation service.  inVentiv will next be providing market assessment services through its consulting arm, Campbell Alliance. Campbell, a health care consulting firm, helps companies sell more effectively in an environment increasingly dominated by third-party payers.

NeuroVive and inVentiv also are discussing a broader expansion of the partnership to include future development and commercialization services for CicloMulsion.

"We are very pleased to extend the collaboration with inVentiv Health, an important step in preparing the market for launch of CicloMulsion in Europe and, later, in the U.S.," said Mikael Bronnegard, CEO of NeuroVive Pharmaceutical. "inVentiv Health's commercial services will provide a valuable platform for optimal market penetration at later stages and when approaching the launch and marketing of the product."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing